Progress in the clinical treatment of oral submucosal fibrosis

WANG Feng-feng; WANG Tao; LI Chuan-zhen

doi:10.16766/j.cnki.issn.1674-4152.002558

Volume 20 Issue 7

Jul. 2022

Turn off MathJax

Article Contents

Article Navigation > Chinese Journal of General Practice > 2022 > 20(7): 1203-1206

WANG Feng-feng, WANG Tao, LI Chuan-zhen. Progress in the clinical treatment of oral submucosal fibrosis[J]. Chinese Journal of General Practice, 2022, 20(7): 1203-1206. doi: 10.16766/j.cnki.issn.1674-4152.002558

Citation:

WANG Feng-feng, WANG Tao, LI Chuan-zhen. Progress in the clinical treatment of oral submucosal fibrosis[J]. Chinese Journal of General Practice, 2022, 20(7): 1203-1206. doi: 10.16766/j.cnki.issn.1674-4152.002558

Citation:

PDF( 439 KB)

Progress in the clinical treatment of oral submucosal fibrosis

doi: 10.16766/j.cnki.issn.1674-4152.002558

1.
School of Stomatology, Hainan Medical University, Haikou, Hainan 570000, China

Funds:

81460105

81960199

Received Date: 2021-10-01
Available Online: 2022-09-23

Abstract

Abstract

Oral submucosal fibrosis (OSF) is a chronic oral mucosal disease characterised by epithelial atrophy, excessive accumulation and degeneration of collagen fibres in the lamina propria and submucosa and changes in microvascular quality. It has no symptoms at the early stage. However, symptoms gradually manifest including limited mouth opening; white, stiff and inelastic mucosa; burning sensation whilst eating, especially spicy and other stimulating foods; dry mouth; and functional decline in chewing, speech and taste. OSF has a tendency to become oral cancer (7%-30%). Therefore, WHO and IARC included in the queue of potential oral malignant diseases. It's a double whammy to the patient's life and spirit. Early intervention in mild OSF patients to slow down or even stop the development of the disease has become particularly important. The prevention and treatment of OSF have been the focus of scholars in China and abroad. In recent years, researchers have been trying to explore more effective methods of prevention and treatment of OSF by means of drug therapy, hyperbaric medicine and surgical treatment. At the same time, the study of OSF pathogenesis continues to deepen. In medicine mainly around Curcuma Longa, Salvia Miltiorrhiza, aloe, placenta extract and so on, in the physiotherapy focus on Hyperbaric medicine, whilst exploring a variety of surgical procedures, both oral function and aesthetic repair of postoperative defects. At present, the effect of OSF is not good, and no definite radical therapy has been found. Individualised treatment and relief of clinical symptoms and signs are still the main ways to treat OSF. In this paper, we summarise the research progress of the treatment of OSF from three aspects of drug therapy, physical therapy and operation therapy to provide a basis for the clinical treatment of OSF by stomatologists.
- Oral submucosal fibrosis,
- Medication,
- Physiotherapy,
- Surgical operation

FullText(HTML)

References(36)

References

[1]	翦新春, 高兴. 口腔黏膜下纤维性变的病因、致病机理、诊断与治疗[J]. 口腔疾病防治, 2021, 29(4): 217-225. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYB202104002.htm JIAN X C, GAO X. Etiology, pathogenesis, diagnosis and treatment of oral submucous fibrosis[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(4): 217-225. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYB202104002.htm
[2]	PENG Q, LI H Y, CHEN J, et al. Oral submucous fibrosis in Asian countries[J]. J Oral Pathol Med, 2020, 49(4): 294-304. doi: 10.1111/jop.12924
[3]	杨博, 符梦凡, 唐瞻贵. 槟榔碱及机械刺激构建大鼠口腔黏膜下纤维化模型[J]. 华西口腔医学杂志, 2019, 37(3): 260-264. https://www.cnki.com.cn/Article/CJFDTOTAL-HXKQ201903008.htm YANG B, FU M F, TANG Z G. Rat model with oral submucous fibrosis induced by arecoline and mechanical stimulation[J]. West China Journal of Stomatology, 2019, 37(3): 260-264. https://www.cnki.com.cn/Article/CJFDTOTAL-HXKQ201903008.htm
[4]	李辉莉, 方厂云, 苏征. 槟榔碱对颊黏膜成纤维细胞增殖及迁移的影响[J]. 国际口腔医学杂志, 2020, 47(1): 32-36. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKQ202001009.htm LI H L, FANG C Y, SU Z. Effects of arecoline on proliferation and migration of human buccal mucosal fibroblasts in vitro[J]. International Journal of Stomatolog, 2020, 47(1): 32-36. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKQ202001009.htm
[5]	JAIN A, TANEJA S. Oral submucous fibrosis in pediatric patients: A systematic review and protocol for management[J]. Int J Surg Oncol, 2019, 2019: 3497136.
[6]	Al-MAWERI S A. Efficacy of curcumin for management of oral submucous fibrosis: A systematic review of randomized clinical trials[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019, 127(4): 300-308. doi: 10.1016/j.oooo.2019.01.010
[7]	ZHANG L, TAN J, LIU Y P, et al. Curcumin relieves the arecoline-induced fibrosis of oral mucosal fibroblasts via inhibiting HIF-1α/TGF-β/CTGF signaling pathway: An in vitro study[J]. Toxicol Res (Camb), 2021, 10(3): 631-638. doi: 10.1093/toxres/tfab046
[8]	LANJEKAR A B, BHOWATE R R, BAKHLE S, et al. Comparison of efficacy of topical curcumin gel with triamcinolone-hyaluronidase Gel individually and in combination in the treatment of oral submucous fibrosis[J]. J Contemp Dent Pract, 2020, 21(1): 83-90. doi: 10.5005/jp-journals-10024-2726
[9]	刘爱丽, 闫振峰, 毛远兴. 泼尼松龙治疗口腔黏膜下纤维性变的临床效果观察[J]. 北京口腔医学, 2021, 29(2): 93-96. https://www.cnki.com.cn/Article/CJFDTOTAL-BJKX202102010.htm LIU A L, YAN Z F, MAO Y X. Clinical effect of prednisolone in the treatment of oral submucous fibrosis[J]. Beijing J Stom, 2021, 29(2): 93-96. https://www.cnki.com.cn/Article/CJFDTOTAL-BJKX202102010.htm
[10]	肖婷, 唐瞻贵. 治疗口腔黏膜下纤维性变常用中药和西药的研究进展[J]. 口腔疾病防治, 2021, 29(11): 771-775. doi: 10.12016/j.issn.2096-1456.2021.11.008 XIAO T, TANG Z G. Research progress in the treatment of oral submucous fibrosis with traditional Chinese medicine and Western medicin[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(11): 771-775. doi: 10.12016/j.issn.2096-1456.2021.11.008
[11]	LIU J, CHEN F, WEI Z, et al. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis[J]. Oral Dis, 2018, 24(5): 706-716. doi: 10.1111/odi.12715
[12]	SADAKSHARAM J, MAHALINGAM S. Evaluation of oral pentoxifylline in the management of oral submucous fibrosis: An ultrasonographic study[J]. Contemp Clin Dent, 2017, 8(2): 200-204. doi: 10.4103/ccd.ccd_1192_16
[13]	KHOLAKIYA Y, JOSE A, RAWAT A, et al. Surgical management of oral submucous fibrosis with "Seagull-nasolabial flap" combined with short-term oral pentoxifylline for preventing relapse[J]. J Stomatol Oral Maxillofac Surg, 2020, 121(5): 512-516. doi: 10.1016/j.jormas.2019.12.015
[14]	张丽, 龙卉, 段开文. 芦荟在口腔临床医学应用中的研究新进展[J]. 口腔医学, 2017, 37(3): 285-288. https://www.cnki.com.cn/Article/CJFDTOTAL-KQYX201703025.htm ZHANG L, LONG H, DUAN K W. New research progress of Aloe vera in dental clinical application[J]. Stomatology, 2017, 37(3): 285-288. https://www.cnki.com.cn/Article/CJFDTOTAL-KQYX201703025.htm
[15]	SÁNCHEZ M, GONZÁLEZ-BURGOS E, IGLESIAS I, et al. Pharmacological update properties of aloe vera and its major active constituents[J]. Molecules, 2020, 25(6): 1324. doi: 10.3390/molecules25061324
[16]	MAJUMDER R, DAS C K, MANDAL M. Lead bioactive compounds of Aloe vera as potential anticancer agent[J]. Pharmacol Res, 2019, 148: 104416. DOI: 10.1016/j.phrs.2019.104416.
[17]	KUMAR R, SINGH A K, GUPTA A, et al. Therapeutic potential of Aloe vera-A miracle gift of nature[J]. Phytomedicine, 2019, 60: 152996. doi: 10.1016/j.phymed.2019.152996
[18]	ANURADHA A, PATIL B, ASHA V R. Evaluation of efficacy of aloe vera in the treatment of oral submucous fibrosis-a clinical study[J]. J Oral Pathol Med, 2017, 46(1): 50-55. doi: 10.1111/jop.12463
[19]	PIYUSH P, MAHAJAN A, SINGH K, et al. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized controlled trial[J]. Oral Dis, 2019, 25(1): 73-79. doi: 10.1111/odi.12947
[20]	TP B, T A G, VARGHESE M, et al. Evaluation of therapeutic efficacy of different treatment modalities in oral submucous fibrosis: A comparative study[J]. J Contemp Dent Pract, 2019, 20(3): 390-394. doi: 10.5005/jp-journals-10024-2527
[21]	DATARKAR A, AKARE A, TAYAL S. Efficacy of prednisolone mouthwash in management of grade Ⅲ oral submucous fibrosis: A newer drug regimen[J]. J Maxillofac Oral Surg, 2020, 19(4): 532-538. doi: 10.1007/s12663-019-01248-3
[22]	郭锦材, 谢辉. 天然药物提取物治疗口腔黏膜下纤维性变的临床研究进展[J]. 临床口腔医学杂志, 2018, 34(11): 692-695. doi: 10.3969/j.issn.1003-1634.2018.11.016 GUO J C, XIE H. Clinical research progress of natural drug extracts in the treatment of oral submucosal fibrosis[J]. J Clin Stomatol, 2018, 34(11): 692-695. doi: 10.3969/j.issn.1003-1634.2018.11.016
[23]	KISAVE P, SHEKHAR V, BABU P S, et al. The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis[J]. J Family Med Prim Care, 2020, 9(5): 2469-2474. doi: 10.4103/jfmpc.jfmpc_268_20
[24]	李晓辉, 张永红. 糖尿病足最新治疗进展[J]. 中华全科医学, 2018, 16(6): 993-997. doi: 10.16766/j.cnki.issn.1674-4152.000272 LI X H, ZHANG Y H. Latest treatment progress of diabetes mellitus[J]. Chinese Journal of General Practice, 2018, 16(6): 993-997. doi: 10.16766/j.cnki.issn.1674-4152.000272
[25]	王琰, 王靖虓, 郭倩倩, 等. 上颌骨弥漫性骨髓炎的临床诊疗及影像学分析[J]. 中华全科医学, 2021, 19(2): 232-235. doi: 10.16766/j.cnki.issn.1674-4152.001775 WANG Y, WANG J X, GUO Q Q, et al. Clinical diagnosis, treatment and imaging analysis of diffuse osteomyelitis of maxilla[J]. Chinese Journal of General Practice, 2021, 19(2): 232-235. doi: 10.16766/j.cnki.issn.1674-4152.001775
[26]	周领航, 谭劲. 高压氧联合醋酸曲安奈德注射液局部封闭治疗口腔黏膜下纤维性变的疗效及对E-钙黏蛋白、转化生长因子-β1表达的影响[J]. 中国医学创新, 2021, 18(14): 39-43. doi: 10.3969/j.issn.1674-4985.2021.14.010 ZHOU L H, TAN J. Efficacy of hyperbaric oxygen combined with triainclnolone acetonide acetate injection in the treatment of oral submucosal fibrosis and its effect on the expression of e-cadherin and transforming growth factor-β1[J]. Medical Innovation of China, 2021, 18(14): 39-43. doi: 10.3969/j.issn.1674-4985.2021.14.010
[27]	姚玉波, 李乐乐, 石琳琳, 等. 高压氧联合药物治疗口腔黏膜下纤维化的效果分析[J]. 实用医药杂志, 2020, 37(2): 130-131. https://www.cnki.com.cn/Article/CJFDTOTAL-QEYY202002013.htm YAO Y B, LI L L, SHI L L, et al. Effect of hyperbaric oxygen combined with drugs on oral submucous fibrosis[J]. Prac J Med & Pharm, 2020, 37(2): 130-131. https://www.cnki.com.cn/Article/CJFDTOTAL-QEYY202002013.htm
[28]	MESHRAM M, ANCHLIA S, SHAH H, et al. Buccal fat pad-derived stem cells for repair of maxillofacial bony defects[J]. J Maxillofac Oral Surg, 2019, 18(1): 112-123. doi: 10.1007/s12663-018-1106-3
[29]	AGRAWAL D, PATHAK R, NEWASKAR V, et al. A comparative clinical evaluation of the buccal fat pad and extended nasolabial flap in the reconstruction of the surgical defect in oral submucous fibrosis patients[J]. J Oral Maxillofac Surg, 2018, 76(3): 676.
[30]	THUKRAL H, ROY CHOWDHURY S K, NAGORI S A. Surgical management of oral submucous fibrosis using buccal fat pad: A retrospective study of 30 cases[J]. Oral Maxillofac Surg, 2018, 22(4): 403-408. doi: 10.1007/s10006-018-0721-y
[31]	SHADAMARSHAN R A, SHARMA R, GREWAL R, et al. Use of the greater palatine pedicled flap for the surgical management of trismus in oral submucous fibrosis[J]. Br J Oral Maxillofac Surg, 2021, 59(8): 888-893. doi: 10.1016/j.bjoms.2020.08.053
[32]	ULAS BALI Z, KEÇECI Y, PABUŞCU Y, et al. Anterolateral thigh flap design by using suprafascial course of the perforator[J]. Ann Plast Surg, 2020, 84(5): 550-553. doi: 10.1097/SAP.0000000000002066
[33]	GUPTA S, PIYUSH P, MAHAJAN A, et al. Fibrotomy with diode laser (980 nm) and habit correlation in oral submucous fibrosis: A report of 30 cases[J]. Lasers Med Sci, 2018, 33(8): 1739-1745. doi: 10.1007/s10103-018-2531-8
[34]	GONDIVKAR D S M, GADBAIL D A R, SARODE D S C, et al. Treatment outcomes of laser therapy in oral submucous fibrosis-a systematic review[J]. J Oral Biol Craniofac Res, 2020, 10(3): 253-258. doi: 10.1016/j.jobcr.2020.05.004
[35]	TIWARI P, BERA R N, CHAUHAN N. What is the optimal reconstructive option for oral submucous fibrosis? A systematic review and meta-analysis of buccal pad of fat versus conventional nasolabial and extended nasolabial flap versus platysma myocutaneous flap[J]. J Maxillofac Oral Surg, 2020, 19(4): 490-497. doi: 10.1007/s12663-020-01373-4
[36]	LI Y H, CHANG W C, CHIANG T E, et al. Mouth-opening device as a treatment modality in trismus patients with head and neck cancer and oral submucous fibrosis: A prospective study[J]. Clin Oral Investig, 2019, 23(1): 469-476. doi: 10.1007/s00784-018-2456-4

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (326) PDF downloads(16)

Progress in the clinical treatment of oral submucosal fibrosis

doi: 10.16766/j.cnki.issn.1674-4152.002558

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Progress in the clinical treatment of oral submucosal fibrosis

doi: 10.16766/j.cnki.issn.1674-4152.002558

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content